Contribute Try STAT+ Today

WASHINGTON — A new analysis from the drug industry’s top lobbying group asserts that many Americans are feeling more of a pinch paying for their prescription drugs because customers are not fully benefitting from health insurers’ negotiations with drug makers.

The new report, shared exclusively with STAT by the Pharmaceutical Research and Manufacturers of America, is the latest in an ongoing volley between drug makers, health insurers, and pharmacy-benefits managers. They are the major players, along with public officials, in the debate over drug affordability.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.